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Background: In COPD, improvements in lung mechanics following bronchodilator, measured
using the forced oscillation technique (FOT), are more sensitive than spirometry at detecting
improvement in lung function following bronchodilator. The relationship between these
improvements in lung mechanics and improvements in functional outcomes, such as exertional
dyspnoea, following bronchodilator, in COPD is unknown.
Methods: 17COPD subjectswere recruited into adoubleblind placebocontrolled randomisedcross
over study. Dyspnoeawas inducedusinga standardised six-minutewalk test (6MWT),andmeasured
by borg score throughout the test. Measurement of respiratory system conductance (Grs), respira-
tory system reactance (Xrs), inspiratory capacity (IC) and spirometryweremade at baseline and 1 h
after a single dose of either 18 mg of tiotropium bromide plus 200 mg salbutamol, or placebo.
Results: Subjects had amean baseline FEV1 of 45.5 11.0% predicted. The bronchodilator induced
reduction in exertional dyspnoea correlated significantly with the increase in Grs (rsZ 0.59,
p Z 0.01) and approached significance with FEV1 (rs Z 0.45, p Z 0.07) but not with FVCc society; DLco, Carbon monoxide diffusion capacity; DLco/VA, Carbon monoxide diffusion capacity
iratory flow limitation calculated as difference between the mean value of Xrs during inspiration and
olume in the first second; FOT, Forced oscillations technique; FVC, Forced vital capacity; IC, Inspi-
ation coefficients; RV, Residual volume; Grs, Respiratory system conductance; Xrs, Respiratory system
esistance; 6 MWT, Six-minute walk test; rs, Spearman’s correlation coefficient; SGRQ, St George
rd deviation; TB þ Sal, 18 mg Tiotropium bromide plus 200 mg salbutamol.
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1346 C. Diba et al.(rsZ 0.30, pZ 0.24), Xrs (rsZ 0.19, pZ 0.47) or IC (rsZ0.08, pZ 0.78). Increase in Grs was the
best and sole predictor of reduction in exertional dyspnoea, explaining 41% of the variance. There
was no additional contribution to the model from the increase in FEV1 or IC.
Conclusion: Bronchodilator induced improvements in exertional dyspnoea in moderate to severe
COPD are predicted by improvements in Grs, measured by FOT, independent of improvements in
spirometry or hyperinflation. The findings suggest that FOT may be useful for measuring response
to bronchodilator in COPD.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
The forced oscillation technique (FOT) measures lung
mechanics during tidal breathing.1,2 Variables obtained using
the FOT can distinguish healthy adults from those with
chronic obstructive pulmonary disease (COPD),3,4 detect
early changes in lung mechanics in smokers5 and track with
recovery fromCOPD exacerbations.6 In COPD, improvements
in lung mechanics following bronchodilator, measured using
the FOT, can occur in the absence of improvements in
spirometry.7,8 Variables obtained using the FOT are more
sensitive than spirometry, since they can detect improve-
ment in lung function following lowerdoses of bronchodilator
and can distinguish between different classes of bronchodi-
lators.7 However, the relationship between these improve-
ments in lung mechanics and improvements in clinically
meaningful outcomes, such as exertional dyspnoea,
following bronchodilator, in COPD is unknown.
Exertional dyspnoea is a common clinical feature of COPD
and diminishes patient’s quality of life since patients reduce
their activities of daily living to accommodate shortness of
breath on exertion. In COPD bronchodilator therapy improves
quality of life by reducing exertional dyspnoea.9,10 Broncho-
dilators reducehyperinflation11e14 and improve ventilation by
relaxing airway smooth muscle, improving airway calibre and
consequently reduce the time constant for lung emptying.2
Respiratory system conductance (Grs), measured by the
FOT, is a measure of airway calibre, and is improved by
bronchodilator.15 Respiratory system reactance (Xrs) is
affected by change in the accessible lung volume, which may
be due to airway closure16 or the development of choke
points, reflecting expiratory flow limitation in the peripheral
airways,17e19 and following bronchodilator is significantly
increased.7,8 It is possible that reduction in airway closure and
increased tidal expansion during exercise, following bron-
chodilator,20 may improve exertional dyspnoea. It is not
known if improvement in airway mechanics, measured using
the FOT, following bronchodilator is associated with
improvement in exertional dyspnoea in COPD.
The six minute walk test (6 MWT) is a self-paced exercise
test used to evaluate functional exercise capacity in COPD
which reflects activities of daily living.21 Since bronchodila-
tors do not change the distance walked during the 6 MWT in
COPD,22e26weused the 6MWT to induceexertional dyspnoea
in a standardised manner. We hypothesised that acute
resting change in respiratory mechanics with bronchodilator
quantifiedbyFOT,would relate to improvement inexertional
dyspnoea measured during the 6 MWT.
The aim of this study was to determine if acute bron-
chodilator induced changes in resting Grs and Xrs measuredby FOT, were associated with improvements in exertional
dyspnoea in moderate to severe COPD.
Methods
Study design
This was an exploratory study in subjects with moderate to
severe COPD. Subjects were recruited into a double blind,
placebocontrolled, randomised, cross over study. In this study
we compared the effects of a single administration of inhaled
tiotropium bromide (18 mg) plus salbutamol (200 mg) (bron-
chodilator) on lung function, 6 MWTand exertional dyspnoea.
Subjects completed a St George Respiratory Questionnaire
(SGRQ) as ameasureofqualityof life.On thefirst visit subjects
underwent a practice 6 MWT to eliminate any learning effects
on subsequent tests. The within-day repeatability of spirom-
etry, respiratoryGrsandXrsand ICwasassessedbymaking two
successive baseline measurements on the first visit. On two
subsequent study visits, subjects had measurements of Grs,
Xrs, expiratory flow limitation (DXrs), IC and spirometry fol-
lowed by a 6 MWTat baseline and 1 h after the administration
of either 18 mg of tiotropium bromide plus 200 mg salbutamol,
or placebo. This study was approved by the Human Ethics
Review Committee of the Sydney South West Area Health
Service (protocol number X03-0241) andwas registered on the
Australian clinical trial registry (ACTRN012605000304639).
Subjects
17 subjects with moderate to severe COPD, according to
the Australian COPDX guidelines,27 were recruited through
newspaper advertising. Subjects had baseline FEV1 < 60%
predicted and FEV1/FVC < 70%, with post bronchodilator
FEV1 < 80% predicted and FEV1/FVC < 70%. Subjects had
a greater than 15 pack year smoking history, could be
current smokers and experienced dyspnoea on exertion.
Subjects with a history of asthma, wheezing, allergic
disease, and orthopaedic disease such as osteoarthritis, or
cardiac disease were excluded from the study. Subjects
attended the laboratory having withheld short-acting anti-
cholinergic and b2-agonist medication for 6-h, long-acting
b2-agonists for 24 h and tiotropium bromide for two weeks
prior to testing.
Pulmonary function testing
All pulmonary function measurements were performed
according to ATS guidelines. FEV1 and FVC were measured
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Figure 1 Cumulative distance walked versus borg score in
a typical COPD subject at baseline and after bronchodilator.
Table 1 Anthropometric and lung function data at
baseline.
Average (SD)
Age (yrs)a 68.5 (57e80)
M:F 13:4
Pack Years 62.7 (27.3)
FEV1 (%pred) 45.5 (11.0)
FVC (%pred) 68.9 (10.5)
Rrs (%pred)b 154.3 (111.0e177.9)
FRC (%pred) 133.4 (34.8)
RV (%pred) 172.1 (50.3)
DLco (%pred) 45.4 (10.7)
6 MWT (%pred) 78.1 (13.1)
SGRQ total score 41.2 (18.4)
Values are mean  SD unless otherwise stated; M, male; F,
female; %FEV1, percent predicted forced expiratory volume in
1 s; %FVC, percent predicted forced vital capacity; %Rrs,
percent predicted respiratory system resistance; %FRC, percent
predicted functional residual capacity; %RV, percent predicted
residual volume; %DLco, percent predicted diffusion capacity; %
6 MWT, percent predicted six-minute walk test; SGRQ, St
George respiratory questionnaire.
a Median (range).
b Median (25the75th interquartile range).
Respiratory system conductance and exertional dysonoea 1347using a Vmax spirometer (Sensormedics 20c, Yorba Linda
USA) and are reported as a percentage of predicted
values.28 Subdivisions of lung volume were measured using
a constant volume body plethysmograph which was cali-
brated daily (Autobox 6200 DL, Sensormedics, Yorba Linda
CA, USA). Diffusing capacity for CO was measured using the
single breath technique (Sensormedics 2200, Yorba Linda
USA). Predicted values were those of Crapo et al for both
lung volumes29 and diffusion capacity.30
Forced oscillation technique (FOT)
FOT measurements were made before spirometry and
measurements were obtained during 1 min of tidal
breathing. Respiratory system resistance (Rrs) was
measured continuously at 6 Hz using the FOT, as described
previously.31 Erroneous and extreme Rrs and Xrs values, due
to glottic closure or leak around the mouthpiece were
automatically identified and excluded as previously
described.32 The mean of the remaining Rrs and Xrs
measurements were calculated. Predicted equation was
that of Brown et al.33 Grs was calculated as the inverse of
Rrs. Expiratory flow limitation was calculated as the
difference between the mean value of Xrs during inspira-
tion and expiration (DXrs) according to the method of
Dellaca et al.17,19 Bronchodilator induced changes were
expressed as percent of baseline for Grs, and as absolute
change from baseline for Xrs and DXrs
Inspiratory capacity
Changes in end-expiratory lung volume were measured by
changes in IC, which was calculated from the FOT volume
trace. After 1 min of tidal breathing to establish a stable
FRC, subjects were asked to take a slow inspiration up tototal lung capacity and then return to functional residual
capacity. Anticipatory breaths prior to inspiration up to
total lung capacity were excluded from analysis. This was
repeated until two measurements were obtained that were
within 60 ml or 5% of each other. The larger of the two
measurements was taken as a measure of IC.34,35
Six-minute walk test
The six-minute walk test (6 MWT) was performed according
to ATS standards21 with slight modifications. Subjects
underwent a practice walk at baseline to eliminate any
learning effects associated with the test.36 Subjects were
instructed to walk back and forth along a 12 m corridor for
6 min. The same course length and layout were used at
each visit allowing for between visit comparisons of
distance walked.36 They were allowed to stop if limited by
symptoms, but were encouraged to resume the test when
possible. Two standard phrases were used to encourage
subjects, “You are doing well” and “Keep up the good
work”. The distance walked was recorded in meters and
reported as percent of predicted values.37
Dyspnoea was measured throughout the 6 MWT, after
every 48 m walked without interrupting the walk. Subjects
used a modified Borg score38 to rate the intensity of “any
sensation of uncomfortable breathing”. The scale ranged
from 0 to 10 and was marked with descriptive terms
including “just noticeable” at 0.5, “moderately uncom-
fortable” at 5, “severely uncomfortable” at 7, to “maximal
discomfort” at 10. Dyspnoea was measured as the slope of
the least squares regression of Borg score versus cumulative
distance walked (Fig. 1). Changes in the slope were
expressed as a percentage of baseline.
Data analysis
All data were analysed using Analyse-It for Excel (Analyse-It
Software Ltd, Leeds, England). Results are expressed as
medians and interquartile ranges unless otherwise stated.
Spearman’s correlation (rs) was used to examine the rela-
tionships between improvement in exertional dyspnoea
associated with bronchodilator inhalation (Borg slope), and
corresponding improvements in FEV1, FVC, Grs, Xrs,DXrs and
IC. Multiple linear regression analyses were used to examine
the relationship between change in exertional dyspnoea and
1348 C. Diba et al.change inFEV1, IC,Grs andXrswithbronchodilator inhalation.
All comparisons were made using a Wilcoxon signed ranks t-
test with a significance level of 0.05. We also determined the
within day repeatability of FEV1, Grs, Xrs and IC, which was
measured by the intra-class correlation coefficients (ICC) and
95% limits ofagreement39 fromrepeatedmeasurements taken
on the baseline study days.
Results
Subject characteristics
At baseline subjects had moderate to severe airway
obstruction, hyperinflation and reduced DLco (Table 1).
There was a significant impairment of quality of life with an
elevatedmean score of the SGRQ. 40 There was considerable
airway narrowing at operating lung volumewith an increased
Rrs. At the time of study enrolment, seven subjects were
taking short-acting b2-agonists, 7 took long-acting b2-
agonists and 13 took anticholinergics. Placebo data are
available for only 13 subjects, because four subjects failed to
withhold medication on the day of testing.
Baseline correlates of exertional dyspnoea
The relationship between exertional dyspnoea and both
FOT and spirometric variables was examined at baseline.
There was a significant association between Borg slope and
Xrs (rsZ0.54, p Z 0.03), but not with Grs (rsZ0.12,
p Z 0.64), % predicted Rrs (rsZ0.12, p Z 0.65), DXrs
(rs Z 0.41, p Z 0.11), % predicted FEV1 (rs Z 0.18,
p Z 0.49), % predicted FVC (rs Z 0.26, p Z 0.31) or IC
(rs Z 0.02, p Z 0.93).
Bronchodilator response
The changes in lung function, exertional dyspnoea and six-
minute walk distance are shown in Table 2 and in Figs. 2 and
3. On the bronchodilator visit three subjects and on the
placebo visit one subject could not perform reproducible ICTable 2 Mean changes in lung function, exercise capacity and
Baseline (n Z 17) TB þ sal (n
FEV1 (L) 1.20 (0.99e1.51) 1.53 (1.12e
FVC (L) 2.82 (2.24e2.98) 3.03 (2.77e
IC (L) 1.81 (1.47e2.08) 2.13 (1.74e
Grs ((L/sec)/cmH2O) 0.20 (0.18e0.23) 0.21 (0.19e
Xrs (cmH2O/(L/sec)) 3.06 ((4.62)e
(2.08))
1.93 ((3
(0.57))**
DXrs (cmH2O/(L/sec)) 2.73 (1.45e4.04) 1.21 (0.49e
DXrs> 2.8 cmH2O/
(L/sec) (n)
6 5
6 MWT (m) 461.3 (387.6e477.5) 456.0 (399.
Borg slope 0.016 (0.010e0.018) 0.011 (0.05
R2-value 0.93 (0.78e0.97) 0.94 (0.79e
Values are median (25the75th interquartile range); p-values are com
change compared with baseline; FEV1, forced expiratory volume in 1 s
Xrs, respiratory system reactance; 6 MWT, six-minute walk test; TB þ
slope of the regression between distance walked and borg; R2-value,manoeuvres, their IC data was excluded from analysis.
After bronchodilator there was a significant increase, when
compared to baseline, in FEV1, FVC, Grs, Xrs, and IC and
a reduction in DXrs, exertional dyspnoea (Borg slope) (Fig. 2
and Table 2) and Borg score at the end of 6 MWT (Fig. 3),
but not distance walked (Table 2). After placebo, there was
no significant change, when compared to baseline, in FEV1,
FVC, Grs, Xrs, DXrs, IC, Borg slope (Fig. 2 and Table 2) or
Borg score at the end of 6 MWT (Fig. 3).
The bronchodilator-induced reduction in exertional
dyspnoea correlated significantly with the increase in Grs
(rs Z 0.59, p Z 0.01, Fig. 4a) and approached significance
with FEV1 (rs Z 0.45, p Z 0.07, Fig. 4b) but not with Xrs
(rs Z 0.19, p Z 0.47), DXrs (rs Z 0.02, p Z 0.93), FVC
(rs Z 0.30, p Z 0.24) or IC (rs Z 0.08, p Z 0.78). A
multiple stepwise linear regression showed that increase in
Grs was the only significant predictor of reduction in
exertional dyspnoea, explaining 41% of the variance. After
accounting for the increase in Grs there was no additional
contribution to the model from the increase in FEV1 or IC.
The increase in FEV1 after bronchodilator correlated with
the reduction in DXrs (rs Z 0.73, p < 0.001) and with the
increase in IC (rsZ 0.54,pZ 0.05). Theabsolute reduction in
DXrs was correlated with the reduction in Xrs (rs Z 0.85,
p < 0.0001) but not with the increase in Grs (rs Z 0.30,
p Z 0.25). The increase in IC after bronchodilator was not
correlated with either the increase in Grs (rs Z 0.25,
pZ 0.38) or the reduction in Xrs (rsZ 0.33, pZ 0.25).Repeatability
On the first visit six subjects could not perform reproducible
ICmanoeuvres, their IC datawas excluded fromrepeatability
analysis. The repeatability of FEV1 (ICCZ 1.00, 95% limits of
agreement Z 0.08) and IC (ICC Z 0.95, 95% limits of
agreementZ0.28) was excellent. The repeatability of Rrs
(ICC Z 0.95, 95% limits of agreement Z 0.99), Grs
(ICC Z 0.94, 95% limits of agreement Z 0.05) and Xrs
(ICC Z 0.95, 95% limits of agreement Z 1.19) were also
very good.exertional dyspnoea with bronchodilator and placebo.
Z 17) Baseline (n Z 13) Placebo (n Z 13)
1.85)** 1.29 (0.94e1.46) 1.28 (0.93e1.56)
3.55)** 2.40 (2.20e3.20) 2.55 (2.25e3.16)
2.35)** 1.69 (1.35e1.89) 1.72 (1.27e1.88)
0.29)* 0.21 (0.19e0.23) 0.19 (0.18e0.22)
.40)e 3.99 ((4.75)e
(1.59))
3.60 ((5.43)e
(1.69))
3.12)* 2.88 (0.80e4.20) 2.19 (0.96e5.11)
7 6
2e509.5) 456.0 (371.8e504.6) 464.0 (360.0e505.2)
e0.016)** 0.015 (0.007e0.027) 0.013 (0.007e0.028)
0.97) 0.95 (0.92e0.97) 0.95 (0.92e0.97)
parisons with baseline **P < 0.001, *P < 0.05; %D, percentage
; FVC, forced vital capacity; Grs, respiratory system conductance;
sal, 18 mg tiotropium bromide and 200 mg salbutamo; Borg slope,
slope of linear regression between distance walked and Borg.
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Figure 2 Percent change in FEV1, Grs and IC from baseline
for both active (closed circle) and placebo (open circle).
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Figure 4 The relationship between changes in airway calibre
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In this study we found that bronchodilator induced improve-
ments in airway calibre, measured by the FOT, correlated
with reduction in exertional dyspnoea in moderate to severe
COPD. The association between improvement in resting Grs
and reduction in exertional dyspnoea during 6 MWT was
independent of the reduction in resting lung hyperinflation.
These findings suggest that FOT may be useful for measuring
response to bronchodilator in COPD.
Improvements in Grs, measured by FOT, reflect a reduc-
tion in the resistive load on the respiratory system. It is
possible that the reduction in exertional dyspnoea in COPD
subjects after bronchodilator in the present study was
a direct consequence of this reduction in resistive load.
However, there are other mechanisms whereby improve-
ment in airway calibre could lead to a reduction in exertional0.0
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Figure 3 Borg at end exercise after baseline and post
treatment walks for both active (TB þ Sal) and placebo visits.
Squares indicate median with 25the75th IQR.
and exertional dyspnoea. Reduction in Borg slope after bron-
chodilator correlated significantly with the increase in Grs
(rsZ 0.59, pZ 0.01, Fig. 3a) and approached significance with
FEV1 (rs Z 0.45, p Z 0.07, Fig. 3b).dyspnoea. Improvement in airway calibre is likely to reduce
expiratory flow limitation and the time constant of the
respiratory system,2 thereby allowing faster emptying of the
lungs. In the present study, reduction in a marker of expira-
toryflow limitation derived from theFOT19was not related to
reduction in exertional dyspnoea. Although there were
significant changes in this marker after bronchodilator, only
six subjects met the criteria for expiratory flow limitation at
baseline,17,18 and five subjects still had flow limitation after
bronchodilator. This finding was consistent with previous
observations,18,41 which found that only a proportion of
COPD patients reduced expiratory flow limitation after
bronchodilator.
Improvement in resting Grs but not resting IC related to
improvement in exertional dyspnoea following acute
administration of bronchodilator. It is well recognised that
dynamic hyperinflation is an important predictor of dysp-
noea during exercise20,35,42,43 and reduction in both
1350 C. Diba et al.resting42,43 and dynamic hyperinflation12,20,34,42,43 following
bronchodilator are associated with reduced exertional
dyspnoea. However, the relationship between improve-
ments in resting IC and exertional dyspnoea is weak
(rZ0.25).42 It is possible that themodest improvements in
baseline Grs with bronchodilator in the present study
contribute to the reduction in exertional dyspnoea by
delaying the onset of dynamic hyperinflation during subse-
quent exercise, and that this effect has more impact on
dyspnoea than does a modest change in resting hyperinfla-
tion. Alternatively, change in hyperinflation, measured by
the change in IC, may be underestimated if there is also
a reduction in TLC44 and this could contribute to a poor
correlation between the changes in resting IC and exertional
dyspnoea. However, changes in TLC after bronchodilator
were not measured in the present study. The finding that an
association between improvements in Grs and exertional
dyspnoea is detectable, evenwithout adjusting for change in
IC, suggests that a simple FOT measurement made during
tidal breathing can provide information about bronchodi-
lator response in COPD that is clinically meaningful.
Respiratory system reactance was a significant predictor
of exertional dyspnoea at baseline in the present study;
however there was no correlation between the improve-
ment in Xrs and the reduction in exertional dyspnoea with
bronchodilator. Respiratory system reactance is propor-
tional to the inertance and elastance of the respiratory
system and, when measured at 6 Hz, Xrs reflects abnor-
mality in the peripheral airways.17,45 Xrs is affected by
changes in the overall volume of the system, due to airway
closure16,17,46 or the development of choke points,
reflecting expiratory flow limitation.17,19 Our finding that
Xrs at baseline was associated with exertional dyspnoea is
consistent with a recent study showing that Xrs at 5 Hz
relates to activity scores calculated using the SGRQ,47 and
supports the view that FOT measurements may provide
information that is relevant to the clinical status of patients
with COPD. However, despite significant improvement in
Xrs, which was probably due to a reduction in expiratory
choke points, this improvement did not relate to improve-
ment in exertional dyspnoea.
This was an exploratory study, in a small number of
subjects designed to determine if improvements in resting
FOT variables could predict a reduction in exertional
dyspnoea following bronchodilator in COPD. The double
blind randomised placebo controlled cross over design
allowed us to minimise any subjective bias in the
measurement of exertional dyspnoea. We used the 6 MWT
to induce exertional dyspnoea in a standardised manner,
because it is thought to reflect the type of daily activities
that COPD patients are likely to undertake. A combination
of the anticholinergic bronchodilator, tiotropium bromide,
and the beta agonist, salbutamol, had no effect on the
distance walked during the 6 MWT. This finding is consistent
with previous studies that have shown either no
effect,22,23,26 or changes in walk distance that, while
statistically significant,48 were considerably less than the
54 m that is considered to be clinically significant.
Previous studies have shown that FOT measurements are
sensitive to the effects of bronchodilator in COPD. The
present study has provided further evidence of the poten-
tial utility of FOT as a marker of bronchodilator response inCOPD by showing that these changes are related to reduc-
tion in exertional dyspnoea, an important clinical outcome.
Furthermore, we have shown that the FOT variables have
excellent repeatability in this population of moderate to
severe COPD. This study only evaluated the acute response
to a single dose of bronchodilator, so further studies are
needed to determine the feasibility of using the FOT to
monitor improvement in respiratory mechanics with pro-
longed bronchodilator treatment. The FOT provides
a simple and sensitive measure of bronchodilator response
in COPD without the need for effort dependent maximal
inspiratory or expiratory manoeuvres.
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